<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89563">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939158</url>
  </required_header>
  <id_info>
    <org_study_id>116892</org_study_id>
    <secondary_id>2013-001083-28</secondary_id>
    <nct_id>NCT01939158</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine</brief_title>
  <official_title>Immunogenicity and Safety Study of 1 and 2 Doses of GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Pneumococcal Vaccine Prevenar 13™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the immediate and long term (up to 5 years)
      immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose
      or as 2 doses to toddlers aged 12 to 14 months. Also, this study will also assess if
      co-administration of GSK Biologicals' MenACWY-TT with the booster dose of Pfizer's Prevenar
      13 adversely impacts the immunogenicity of either of the vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Medicines Control Council (MCC) authorities requested that subjects be screened for HIV
      testing prior to study enrolment in South Africa to ensure that only HIV negative
      participants are enrolled. As such, HIV rapid test was added at Visit 1 only for subjects in
      South Africa. Subjects previously screened HIV positive will be excluded.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines in terms of rSBA titres</measure>
    <time_frame>1 month after administration of 1 dose of MenACWY-TT in the ACWY1d, ACWY2d and Co-ad groups (Month 1)</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines in terms of rSBA titres</measure>
    <time_frame>At Year 1</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8, ≥ 1:128 and titres in the ACWY1d and ACWY2d groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines in terms of rSBA titres</measure>
    <time_frame>At Year 3</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8, ≥ 1:128 and titres in the ACWY1d and ACWY2d groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines in terms of rSBA titres</measure>
    <time_frame>At Year 5</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8, ≥ 1:128 and titres in the ACWY1d and ACWY2d groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines in terms of antibody concentration</measure>
    <time_frame>1 month after administration of Prevenar 13 (Month 1)</time_frame>
    <description>Anti-pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations in the Co-ad and PCV-13 groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines in terms of rSBA titres</measure>
    <time_frame>1 month after administration of 2 doses of MenACWY-TT in the ACWY2d group (Month 3)</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of hSBA titres</measure>
    <time_frame>1 month after administration of 1 dose of MenACWY-TT in a subset of subjects in the ACWY1d and ACWY2d groups (Month 1) and 2 doses in the ACWY2d group (Month 3)</time_frame>
    <description>Percentage of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY titres ≥ 1:4, ≥ 1:8 and titres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of rSBA titres</measure>
    <time_frame>1 month after administration of 1 dose of MenACWY-TT (Month 1)</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8, ≥ 1:128 and titres in the PCV-13 group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of rSBA titres</measure>
    <time_frame>1 month after administration of 1 dose of MenACWY-TT (Month 1)</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:128 and titres in the ACWY1d, ACWY2d and Co-ad groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of hSBA titres</measure>
    <time_frame>At Years 1, 3 and 5</time_frame>
    <description>Percentage of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY titres ≥ 1:4, ≥1:8 and titres in a subset of subjects in the ACWY1d and ACWY2d groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of rSBA titres</measure>
    <time_frame>At Years 1, 3 and 5</time_frame>
    <description>Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres ≥ 1:8, ≥1:128 and titres in the Co-ad and PCV-13 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of antibody concentration</measure>
    <time_frame>One month after administration of Prevenar 13 (Month 1)</time_frame>
    <description>Percentage of subjects with anti-pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F antibody concentrations ≥ 0.15 µg/ml, ≥ 0.26 µg/ml and ≥ 0.35 µg/ml in the Co-ad and PCV-13 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccines (on secondary readouts) in terms of OPA titres</measure>
    <time_frame>One month after administration of Prevenar 13 (Month 1)</time_frame>
    <description>Percentage of subjects with anti-pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F OPA titres ≥ 1:8 and titres in the Co-ad and PCV-13 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local and general symptoms</measure>
    <time_frame>Within 4 days (Day 0 - Day 3) after each study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse events</measure>
    <time_frame>Within 31 days (Day 0 - Day 30) after any study vaccination</time_frame>
    <description>Occurrence of unsolicited AEs according to the Medical Dictionary for Regulatory Activities (MedDRA) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)</measure>
    <time_frame>From Month 0 to Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of SAEs related to study vaccine administration</measure>
    <time_frame>From the first receipt of study vaccine until study end (Year 5)</time_frame>
    <description>Occurrence of SAEs related to study vaccine administration and any event related to lack of vaccine efficacy (i.e. meningococcal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of New Onset Chronic Illnesses (NOCIs)</measure>
    <time_frame>From Month 0 to Month 9</time_frame>
    <description>E.g. asthma, autoimmune disorders, type 1 diabetes, allergies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Infections, Meningococcal</condition>
  <arm_group>
    <arm_group_label>ACWY1d group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 1 dose of the MenACWY-TT vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACWY2d group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co-ad group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV-13 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal vaccine GSK134612</intervention_name>
    <description>1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region</description>
    <arm_group_label>PCV-13 group</arm_group_label>
    <arm_group_label>ACWY2d group</arm_group_label>
    <arm_group_label>Co-ad group</arm_group_label>
    <arm_group_label>ACWY1d group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13™</intervention_name>
    <description>1 dose administered intramuscularly in the right anterolateral thigh or deltoid region</description>
    <arm_group_label>PCV-13 group</arm_group_label>
    <arm_group_label>Co-ad group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion
             of the investigator, can and will comply with the requirements of the protocol.

          -  A male or female between, and including, 12 and 14 months of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Vaccination records showing the completion of the full primary vaccination schedule
             with Prevenar 13 and Diphtheria, Tetanus and Pertussis (DTP) containing vaccine
             according to local recommendations at least 5 months before the study entry.

        Exclusion Criteria:

          -  Child in care.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants
             or other immune-modifying drugs within six months prior to the first vaccine dose.
             For corticosteroids, this will mean prednisone 0.5 mg/kg/day, or equivalent. Inhaled
             and topical steroids are allowed.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within the period starting 30 days before and ending 30 days after the dose of
             vaccines, with the exception of a licensed inactivated influenza vaccine. Measles,
             Mumps Rubella (MMR) vaccine or Measles Mumps Rubella and Varicella (MMRV) vaccine can
             be co-administered with MenACWY-TT and/or Prevenar 13. A DTPa containing vaccine can
             be administered after the last blood sampling (at Visit 2 or 4 depending on the
             group).

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product (pharmaceutical product or device).

          -  Previous vaccination against Neisseria meningitidis.

          -  Previous booster vaccination against Streptococcus pneumoniae.

          -  Previous booster vaccination against Corynebacterium diphtheriae, Clostridium tetani
             and Bordetella pertussis.

          -  History of meningococcal disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital
             or secondary), including human immunodeficiency virus (HIV) infection, based on
             medical history and physical examination (no laboratory testing required)*

               -  Note: With the exception of HIV rapid testing which will be done for subjects in
                  South Africa.

          -  Family history of congenital or hereditary immunodeficiency.

          -  History of any reaction or hypersensitivity, including to diphtheria toxoid, likely
             to be exacerbated by any component of the vaccines.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurological disorders or seizures, including Guillain-Barré syndrome
             (GBS). History of a simple, single febrile seizure is permitted.

          -  Acute disease and/or fever at the time of enrollment.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>14 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benesov</city>
        <zip>256 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decin</city>
        <zip>405 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Domazlice</city>
        <zip>34401</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kladno</city>
        <zip>272 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nachod</city>
        <zip>547 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odolena voda</city>
        <zip>25070</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>70800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrov</city>
        <zip>363 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 6</city>
        <zip>1600</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trutnov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panama</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalupe, La Chorrera</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Panama</country>
    <country>South Africa</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>August 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Co-administration</keyword>
  <keyword>Safety</keyword>
  <keyword>Persistence</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Prevenar 13</keyword>
  <keyword>Meningococcal vaccine</keyword>
  <keyword>Toddlers</keyword>
  <keyword>5 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
